Literature DB >> 34515791

The blood-brain barrier limits the therapeutic efficacy of antibody-drug conjugates in glioblastoma.

Roger Abounader1,2,3, David Schiff2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34515791      PMCID： PMC8643443          DOI： 10.1093/neuonc/noab223

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  7 in total

1.  Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review.

Authors:  Michael A Vogelbaum; Daria Krivosheya; Hamid Borghei-Razavi; Nader Sanai; Michael Weller; Wolfgang Wick; Riccardo Soffietti; David A Reardon; Manish K Aghi; Evanthia Galanis; Patrick Y Wen; Martin van den Bent; Susan Chang
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

2.  Brain Access of Monoclonal Antibodies as Imaged and Quantified by 89Zr-Antibody PET: Perspectives for Treatment of Brain Diseases.

Authors:  Sophie E M Veldhuijzen van Zanten; Philip C De Witt Hamer; Guus A M S van Dongen
Journal:  J Nucl Med       Date:  2019-02-08       Impact factor: 10.057

Review 3.  Novel HER2-targeted therapies for HER2-positive metastatic breast cancer.

Authors:  Siddharth Kunte; Jame Abraham; Alberto J Montero
Journal:  Cancer       Date:  2020-07-28       Impact factor: 6.860

4.  Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies.

Authors:  Frederick F Lang; Mark R Gilbert; Vinay K Puduvalli; Jeffrey Weinberg; Victor A Levin; W K Alfred Yung; Raymond Sawaya; Gregory N Fuller; Charles A Conrad
Journal:  Neuro Oncol       Date:  2002-10       Impact factor: 12.300

5.  A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.

Authors:  Andrew M Scott; Fook-Thean Lee; Niall Tebbutt; Rebecca Herbertson; Sanjeev S Gill; Zhanqi Liu; Effie Skrinos; Carmel Murone; Timothy H Saunder; Bridget Chappell; Anthony T Papenfuss; Aurora M T Poon; Wendie Hopkins; Fiona E Smyth; Duncan MacGregor; Lawrence M Cher; Achim A Jungbluth; Gerd Ritter; Martin W Brechbiel; Roger Murphy; Antony W Burgess; Eric W Hoffman; Terrance G Johns; Lloyd J Old
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-28       Impact factor: 11.205

6.  Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.

Authors:  Bianca-Maria Marin; Kendra A Porath; Sonia Jain; Minjee Kim; Jason E Conage-Pough; Ju-Hee Oh; Caitlyn L Miller; Surabhi Talele; Gaspar J Kitange; Shulan Tian; Danielle M Burgenske; Ann C Mladek; Shiv K Gupta; Paul A Decker; Madison H McMinn; Sylwia A Stopka; Michael S Regan; Lihong He; Brett L Carlson; Katrina Bakken; Terence C Burns; Ian F Parney; Caterina Giannini; Nathalie Y R Agar; Jeanette E Eckel-Passow; Jennifer R Cochran; William F Elmquist; Rachael A Vaubel; Forest M White; Jann N Sarkaria
Journal:  Neuro Oncol       Date:  2021-12-01       Impact factor: 13.029

7.  INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.

Authors:  Martin Van Den Bent; Marica Eoli; Juan Manuel Sepulveda; Marion Smits; Annemiek Walenkamp; Jean-Sebastian Frenel; Enrico Franceschi; Paul M Clement; Olivier Chinot; Filip De Vos; Nicolas Whenham; Paul Sanghera; Michael Weller; H J Dubbink; Pim French; Jim Looman; Jyotirmoy Dey; Scott Krause; Pete Ansell; Sarah Nuyens; Maarten Spruyt; Joana Brilhante; Corneel Coens; Thierry Gorlia; Vassilis Golfinopoulos
Journal:  Neuro Oncol       Date:  2020-05-15       Impact factor: 12.300
  7 in total
  2 in total

Review 1.  Naturally Occurring Antioxidant Therapy in Alzheimer's Disease.

Authors:  Andrila E Collins; Tarek M Saleh; Bettina E Kalisch
Journal:  Antioxidants (Basel)       Date:  2022-01-23

2.  Biodistribution Analysis of an Anti-EGFR Antibody in the Rat Brain: Validation of CSF Microcirculation as a Viable Pathway to Circumvent the Blood-Brain Barrier for Drug Delivery.

Authors:  Ghazal Naseri Kouzehgarani; Pankaj Kumar; Susan E Bolin; Edward B Reilly; Didier R Lefebvre
Journal:  Pharmaceutics       Date:  2022-07-12       Impact factor: 6.525
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.